20th century's greatest engineering achievements : http://www.greatachievements.org/greatachievements/indexp.html> 1. Electrification In the 20th century, widespread electrification gave us power for our cities, factories, farms, and homes -and forever changed our lives. Thousands of engineers made it happen, with innovative work in fuelsources, power generating techniques, and trans
Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.
Erityisesti laatu viagra tästä kaupasta voi taata henkilökohtaisesti levitra Paras laatu kehotan Teitä miellyttää.
300 Northfield Road
Bedford, OH 44146
MATERIAL SAFETY DATA SHEET
Section I - IDENTITY
Common/Trade Name: Methotrexate Injection, USP (25 mg/mL; 2mL, 4mL, 8mL and 10mL)
Chemical Name: N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-
Synonyms: Methotrexate, MTX sodium, L-Glutamic Acid
Emergency Telephone Number: Chemtrec:
Telephone Number for Info.:
Medical Emergency: Professional Services: 1(800)521-5169
Section II - HAZARDOUS INGREDIENTS/COMPOSITION INFORMATION
% CAS# OSHA PEL ACGIH TLV Recommended
Sodium Hydroxide and Hydrochloric Acid for pH adjustment of 8.5
Methotrexate is a sterile injectable liquid drug provided in a vial.
Section III - HEALTH HAZARD DATA
Routes of Entry: Exposure to this product could occur by accidental ingestion, inhalation, or
Health Hazard (Acute & Chronic): Methotrexate is a cytotoxic anticancer drug used to treat a variety
of cancers. It can affect the digestive and central nervous systems. Chronic exposures cause changes in the blood forming system, damage to bone marrow tissues, and possible liver damage. Allergic reaction may also result. Carcinogenicity: NTP? NO
IARC Monographs? Group III (Inconclusive
OSHA Regulated? NO
Methotrexate may cause cancer and may be mutagenic, teratogenic, and fetotoxic. Signs & Symptoms of Exposure: Nausea, abdominal distress, chills, fever, fatigue,
dizziness, mood disorders, irritation of eyes, skin, respiratory system, and possible allergic reaction may occur. Medical Conditions Generally Aggravated by Exposure: Blood, digestive system, and
kidney/liver disorders may be aggravated upon exposure. BVL Hazard Category: 4
Section IV - FIRST AID MEASURES
Eye Exposure: Flush eyes with large volumes of water for 15 minutes.
Skin Exposure: Wash skin with cool, soapy water.
Ingestion: If ingestion occurs, flush mouth with water and seek medical attention.
Inhalation: If difficulty breathing, administer oxygen. Seek attention of a physician immediately. If
necessary, provide artificial respiration. NOTE to physician: Calcium Leucovorin is a potent agent for neutralizing the immediate toxic effects
of Methotrexate on the blood forming system.
Section V - FIRE AND EXPLOSION HAZARD DATA
Flash Point (Method Used): NONE Flammable Limits: LEL: NA UEL: NA
Extinguishing Media: Use water or an ABC multi-purpose extinguisher
Special Fire Fighting Procedures: As with all fires, evacuate personnel to a safe area. Fire fighters
should wear a self-contained breathing apparatus (SCBA) to avoid inhalation of smoke. Product is aqueous-based and is not expected to present a fire hazard concern. Unusual Fire/Explosion Hazards: NONE
Section VI - ACCIDENTAL RELEASE INFORMATION
Release to Land: Absorb Methotrexate solution with absorbent materials and dispose of according to
Release to Air: If aerosolized, reduce exposures by ventilating the area; clean up spill immediately to
Release to Water: Refer to local water authority. Drain disposal is not recommended; however, refer
to local, state, and federal disposal guidelines.
Section VII - PRECAUTIONS FOR SAFE HANDLING AND USE
Steps to be taken in case material is released or spilled: See Section VI above; wear latex or nitrile
gloves, protective clothing, and safety glasses when cleaning spills. A half-mask air purifying respirator with HEPA cartridges (P100) See Section VI above; wear latex or nitrile gloves and safety glasses. For larger spills, additional protective clothing and respirator protection may be needed such as chemical protective coveralls, boots, double gloves (neoprene), and self contained breathing apparatus (SCBA). Waste Disposal Method: Incinerate in an approved/permitted incinerator. Refer to federal, state, and
Precautions to be taken in handling and storing: Store at 15-30°C; protect from light.
Other Precautions: Follow OSHA guidelines for safe handling of cytotoxic products
Section VIII - CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT
Respiratory Protection: Under normal use, a respirator is not required. If aerosols are generated, a
half-mask respirator with HEPA cartridges may be used. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR 1910.134. Ventilation: Use in a Class II Type B biological safety cabinet or in a well-ventilated area.
Protective Gloves: Nitrile or latex
Eye Protection: Safety glasses or goggles
Other Protective Clothing or Equipment: Lab coat
Work/Hygienic Practices: Wash hands following use. No eating, drinking, or smoking while
Section IX - PHYSICAL/CHEMICAL CHARACTERISTICS
Liquid Specific Gravity: Approximate = 1
Appearance and Odor: Yellowish-orange, clear liquid with no odor
Melting Point: Not applicable
>100°C Evaporation Rate: Approximate to water
Vapor Pressure: Not applicable
Solubility in Water: insoluble
Vapor Density: Not applicable
Section X - STABILITY AND REACTIVITY DATA
Incompatibility (Materials to Avoid): Oxidizers and water reactive materials
Hazardous Decomposition or Byproducts: Products of decomposition may include hazardous
byproducts such as nitrogen oxides, carbon monoxide, and carbon dioxide. Hazardous Polymerization: Will not occur
Conditions to Avoid: Store away from strong oxidizers or water reactive materials
Section XI - TOXICOLOGICAL INFORMATION
Toxicity data is for Methotrexate (active drug substance): RTECS # MA1225000
LD50 rat, oral = 135 mg/kg LD50 mouse, oral = 146 mg/kg LD50 rat, intraperitoneal = 6 mg/kg LD50 rat, intraveneous = 14 mg/kg LD50 mouse, intraperitoneal = 50 mg/kg LD50 mouse, unreported = 69 mg/kg Additional reproductive health data is available from the National Institute for Occupational Safety and Health (NIOSH) Registry of Toxic Effects of Chemical Substances (RTECS). Section XII - ENVIRONMENTAL IMPACT INFORMATION
Information is currently not available on the environmental impact of Methotrexate. Handle in a manner
to prevent spills or releases to the environment.
Section XIII - DISPOSAL INFORMATION
Dispose of by incineration at an approved/permitted facility according to
local, state, and federal regulations.
Section XIV - TRANSPORTATION INFORMATION
Methotrexate is not classified as a DOT hazardous material.
Methotrexate is not a Marine Pollutant.
Section XV - REGULATORY INFORMATION
SARA 313 listed?: NO CERCLA listed?: NO RCRA listed?: NO Listed on California’s Proposition 65 List as Group D
Section XVI - OTHER DATA
Use of this product should be through or under the direction of a physician. This MSDS does not address the therapeutic use of this material. Hospital personnel preparing or administering parenteral antineoplastic agents should wear disposable latex gloves, safety glasses, a closed-front gown with cuffs, and respiratory protection. Preparation of all antineoplastic agents should be done in a Class II laminar flow hood or biological safety cabinet with exhaust air discharged external to the room environment. All needles, syringes, vials, and other equipment or disposable clothing that have contacted this agent Persons administering this drug to patients must be careful to avoid needle sticks to syringes and other sharps used in the administration. All needle sticks must be reported to your company management. BVL Hazard Category Definitions (internal hazard ranking used by Ben Venue Laboratories): 1 = Low Toxicity 2= Moderate Toxicity 3 = Potent or Toxic 4 = Highly Potent or Toxic 5 = Extremely Potent or Toxic OEL=Occupational Exposure Limit. An internal limit set by Ben Venue Laboratories for the recommended limit of employee exposure to airborne dusts or aerosols that should not be exceeded over an eight-hour time-weighted average. Methotrexate is considered a Hazardous Drug as described in the NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Employees who prepare or administer hazardous drugs or who work in areas where these drugs are used should follow specific handling guidelines in order to prevent exposure to these agents in the air or on work surfaces, clothing, or equipment. The Following Guidance Information is excerpted from the NIOSH Alert:
Elements of a Hazardous Drug Handling Program include: • Establishment and implementation of written policies and protocols to ensure the safe handling of oncolytic and/or potent drugs, including receipt of product. • Training and education of employees on the recognition, evaluation and control of • Effective Planning and design of the workplace • Use of best practice control measures and specialized equipment such as ventilated cabinets or isolators designed for worker protection • Wearing recommended personal protective equipment • An integrated health surveillance program that: includes the assessment and counseling of prospective employees before they commence any work involving oncolytic and/or potent drugs and related waste Published guidance on the handling and transport of cytotoxic drugs:
NIOSH Alert – Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings National Study Commission on Cytotoxic Exposure: Recommendation for handling Cytotoxic Agents: This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this MSDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user’s responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this MSDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product
LIPPINCOTT WILLIAMS and WILKINS JOURNAL NAME: MPH ARTICLE NO: QUERIES AND / OR REMARKS Details Required Author's Response Please confirm whether ‘Nifurtimox Treatment of Neuroblastoma’ as the short running title is ok. If not, please provide an appropriate short running title for the article (approx. 45 characters). Please provide the city and state names for affiliat